Clariness and SubjectWell share their perspective on what this new chapter means for patient recruitment and the life sciences ecosystem.
Earlier this week, Clariness and SubjectWell announced their merger. It is not hyperbole to say that this announcement is also something larger: a transformative moment for the entire life sciences ecosystem.
Together, the organizations are not simply getting bigger. Both organizations have delivered confidence in enrollment for years, bringing a combined experience across nearly 2,500 studies. By coming together, that strength is amplified, expanded globally, and made even more reliable, resilient, and scalable.
For years, patient recruitment has been one of the most persistent challenges in clinical research. Trials often launch with optimism and stall in reality: sponsors and CROs build plans only to revise them, patients who could benefit struggle to find trials, and studies seeking diversity face barriers to achieving it.
This merger is a direct response to that challenge.
To learn more about the Clariness-SubjectWell merger, read the full press release below.
Why this matters to sponsors
Sponsors face increasing complexity: shrinking timelines, global protocols, and more precise eligibility criteria, all while pressure mounts to deliver breakthroughs faster.
Built on combined expertise, technology, and global reach, the organization offers sponsors a single partner that can:
- Support global clinical trials across 60+ countries with local, native-speaking teams
- Deliver more reliable enrollment backed by 42,000+ randomizations across 400+ indications
- Connect sponsors to 15M patients through one of the world’s largest patient databases
- Accelerate enrollment timelines with purpose-built technology and human-centered solutions
This is not scale for the sake of scale. It is scale that reduces uncertainty, strengthens planning, and gives sponsors a greater sense of control throughout the enrollment lifecycle.
The combined Clariness + SubjectWell platform offers something rare: confidence at global scale.
Why this matters to CROs
For CROs, patient recruitment is often the largest variable in study timelines. The industry has relied on fragmented vendors for too long, leading to inconsistency, inefficiency, and surprises.
This merger creates a recruitment partner built for how CROs operate today: global, fast‑moving, collaborative, and accountable end-to-end.
Together, Clariness and SubjectWell can:
- Support multi‑country studies with consistent high‑quality execution
- Scale rapidly when protocols expand or criteria shift, with experience screening 3.7M+ patients
- Function as a true strategic extension of CRO teams, trusted by 15,000+ sites
CROs now gain a partner built around confidence, flexibility, and transparency.
Why this matters to patients
At the center of every study is a human decision, one that is often filled with hope, uncertainty, and the desire to make informed choices.
This merger strengthens our ability to reach, support, and empower patients where they are.
Together, Clariness and SubjectWell offer:
- Access to a broader range of clinical trial opportunities through expanded global reach
- Genuine human support, aided by a team of 80 enrollment specialists
- More inclusive trials that reflect real‑world diversity
Clinical trials only work when patients can find and trust them. This merger makes it easier, more accessible, and more equitable for millions of people.
Why this matters to the life sciences ecosystem
Clinical research does not advance in silos. It thrives when sponsors, CROs, sites, and patients are aligned around a shared mission: bringing better treatments to patients faster.
One of the ecosystem’s most persistent challenges has always been patient recruitment. When this bottleneck is reduced:
- Trials complete sooner
- Costs decrease
- Innovation accelerates
- Patients benefit earlier
Scale – when coupled with responsibility and expertise – becomes a powerful force multiplier.
What happens next
With any merger, it’s natural to wonder what changes, and what doesn’t. The most important message is this: Nothing disrupts. Everything strengthens.
Commitments include:
- Existing teams remaining in place
- Primary points of contact staying the same
- Deliverables and commitments remaining unchanged
- Accountability staying where it belongs
As the organizations move toward a unified structure under the Clariness brand, priorities remain clear: continuity, quality, and trust. The integration enables deeper investment in people, technology, and processes that give customers reduced uncertainty and stronger confidence in their enrollment efforts.
The combined organization remains fully invested in:
- Reducing uncertainty in global recruitment
- Expanding access so more patients can participate
- Strengthening diversity across trials
- Innovating new ways to bridge patients, sites, and opportunities
- Accelerating progress across the entire ecosystem
At its core, this merger is not about consolidation, but about what’s possible for science, timelines, for trust, and most importantly, for patients.
And this is only the beginning.